Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian cancer
Open label, multicenter, phase 2 study of farletuzumab ecteribulin, a folate receptor alpha-targeting antibody-drug conjugate, alone and in combination with lenvatinib in platinum-resistant ovarian cancer Wenham, R. M., Ghamande, S., Oaknin, A., Berek, J. S., Perez-Fidalgo, J., Sentis, P., Matei, D., Yonemori, K., Yunokawa, M., Song, T., Hawk, N., Scott, R., Makker, V. ELSEVIER. 2026View details for DOI 10.1016/j.ijgc.2025.104404
View details for Web of Science ID 001716801000020